Amarin Corp

NASDAQ: AMRN
$0.88
+$0.00 (+-0.5%)
Closing price April 24, 2024
Amarin Corp is a Dublin-based pharmaceutical company focused on creating treatments for cardiovascular diseases. Its flagship product, VASCEPA, is an omega-3 fatty acid prescription used to lower triglyceride levels in adults with severe hypertriglyceridemia, contributing to heart health. Amarin markets its products mainly through wholesalers and specialty pharmacies, also collaborating with Mochida Pharmaceutical for further development. Originally named Ethical Holdings, Amarin has been advancing heart disease treatment since its inception in 1989.
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Tuesday's top analyst upgrades and downgrades included Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP Semiconductors, Salesforce.com, Sirius XM, Slack and Yelp.
Amarin has been right in the middle of this recent market sell-off, and while shares have been halved, the stock could be poised for a strong recovery. All the pieces seem to be there.
Friday's top analyst calls included Amazon, Adobe, AMD, Apple, BlackRock, Broadcom, Caterpillar, Deere, Microsoft, Morgan Stanley, Oracle and Slack.
Shares of Amarin have plunged in recent months. Even more troubling, there appears to no catalyst to drive them higher.
Tuesday's top analyst upgrades, downgrades and initiations included AbbVie, Apple, Arconic, CenturyLink, eHealth, Nvidia, Salesforce.com, Tesla and Teva Pharmaceutical.
Amarin is a development-stage biotechnology company with one FDA-approved treatment, a cardiovascular disease drug with no real competition. The company looks well-poised to boost sales in 2020 and...
Monday's top analyst upgrades, downgrades and initiations included Alphabet, Apple, Bank of America, Citigroup, Dollar Tree, Nordstrom, Salesforce, Travelers and JD.com.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of December.
Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune, Schlumberger and Transocean.
Monday's top analyst upgrades, downgrades and initiations included Amarin, Bank of America, Citigroup, JPMorgan, Liberty SiriusXM, Microsoft, Tesla, TripAdvisor, Twitter and Workday.
Tuesday's top analyst upgrades, downgrades and initiations included AECOM, Arconic, Bed Bath & Beyond, Dollar General, eBay, Grubhub, Lowe's, Nvidia, Stitch Fix and 3M.
Amarin shares dropped on Friday after the firm announced that it received notice from the FDA that delays a pending supplemental new drug application.
24/7 Wall St. has tracked nine stocks that took big hits in the after-hours trading session on Wednesday, July 17, 2019.
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.